Akonni Biosystems Licenses USAMRIID IP to Develop Molecular Tests for Biothreat Agents

The agreement provides Akonni access to nucleic acid sequences, primers, and probes for several important biothreat agents, which it will incorporate into molecular tests on its TruArray and TruSentry platforms.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.